Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611092 | 0.85 | KDR (0.48) | PIK3CAPIK3R1MTOREPHX1HTT | |
| SCHEMBL29728353 | 0.85 | KDR (0.48) | PIK3CAPIK3R1MTOREPHX1HTT | |
| SCHEMBL23140059 | 0.85 | NOTUM (0.42) | PIK3CAPIK3R1MTOREPHX1PIK3C3 | |
| SCHEMBL17059109 | 0.83 | PIK3CA (0.49) | PIK3CAPIK3R1MTORL3MBTL1HDAC4 | |
| SCHEMBL16908092 | 0.81 | GSK3B (0.43) | EPHX1GCKHTTMEN1NPC1 | |
| SCHEMBL17899122 | 0.81 | PIK3CA (0.48) | PIK3CAPIK3R1MTORL3MBTL1HDAC4 | |
| SCHEMBL897009 | 0.80 | PIK3CA (0.50) | PIK3CAPIK3R1MTORL3MBTL1HDAC4 | |
| SCHEMBL20772248 | 0.79 | L3MBTL1 (0.52) | L3MBTL1HDAC4HDAC6PTK2PIK3C3 | |
| SCHEMBL13016572 | 0.78 | CYP3A4 (0.43) | PIK3R1EPHX1EGFRMEN1KMT2A | |
| SCHEMBL16492247 | 0.77 | ASPH (0.45) | EPHX1DHODHHTTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637468-B2 | Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG (CH) | 2017-05-02 | — | — | US | claimed |
| EP-2912030-B1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | NOVARTIS AG (CH) | 2016-08-31 | — | — | EP | claimed |
| US-20150246897-A1 | Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS PHARMA AG (CH) | 2015-09-03 | — | — | US | claimed |
| EP-2912030-A1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | Novartis AG (CH) | 2015-09-02 | — | — | EP | claimed |
| WO-2014064058-A1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | NOVARTIS AG (CH) | 2014-05-01 | — | — | WO | claimed |
| US-9637468-B2 | Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG (CH) | 2017-05-02 | — | — | US | disclosed |
| US-9637468-B2 | Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG (CH) | 2017-05-02 | — | — | US | disclosed |
| US-9637468-B2 | Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | NOVARTIS AG (CH) | 2017-05-02 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| WO-2014064058-A1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | NOVARTIS AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014064058-A1 | IMPROVED PROCESS FOR MANUFACTURING 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE | NOVARTIS AG (CH) | 2014-05-01 | — | — | WO | disclosed |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2621908-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044727-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044727-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, TYMS | PIK3CA 879/4885PIK3R1 4209/4885MTOR 1599/4885 |
| US-20150246897-A1 | Process for Manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine | PAH, QDPR, NISCH | PIK3CA 890/4885PIK3R1 3293/4885MTOR 2016/4885 |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | PIK3CA 602/4885PIK3R1 4000/4885MTOR 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.